A multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 77, Issue 6, 2016, Pages 799-806

  Kantrowitz, Joshua T ^a   Sharif, Zafar ^a   Medalia, Alice ^a   Keefe, Richard S E ^b   Harvey, Philip ^c   Bruder, Gerard ^a   Barch, Deanna M ^d   Choo, Tse ^a   Lee, Seonjoo ^a   Lieberman, Jeffrey A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LURASIDONE;

ADULT; ARTICLE; COGNITIVE ASSESSMENT INTERVIEW; COGNITIVE DEFECT; COGNITIVE FUNCTION TEST; COGNITIVE REMEDIATION THERAPY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; MULTICENTER STUDY; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; UNIVERSITY OF CALIFORNIA SAN DIEGO PERFORMANCE BASED SKILLS ASSESSMENT BRIEF; ADOLESCENT; AUDITORY PERCEPTUAL DISORDERS; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PSYCHOLOGY; PSYCHOTIC DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AUDITORY PERCEPTUAL DISORDERS; COGNITIVE REMEDIATION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84976384886     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m09998     Document Type: Article

References (41)

1. Mohamed S, Rosenheck R, Swartz M, et al. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry. 2008;165(8):978-987. doi:10.176/api.ajp.208.071713
2. Nielsen RE, Levander S, Kjaersdam Tells G, et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131(3):185-196. doi:10.1/acps.12374
3. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115-1122. doi:10.101/archpsyc.64.10.15
4. Keefe RS, Bilder RM, Davis SM, et al; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.101/archpsyc.64.6.63
5. Wykes T, Huddy V, Cellard C, et al. A metaanalysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-485. doi:10.176/api.ajp.2010.106085
6. Kurtz MM. Cognitive remediation for schizophrenia: current status, biological correlates and predictors of response. Expert Rev Neurother. 2012;12(7):813-821. doi:10.1586/ern.12.71
7. Wykes T, Reeder C, Landau S, et al. Cognitive remediation therapy in schizophrenia: randomised controlled trial. Br J Psychiatry. 2007;190(5):421-427. doi:10.192/bjp.bp.106.026575
8. Javitt DC. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol. 2009;5(1):249-275. doi:10.146/anurev.clinpsy.032408.153502
9. Kantrowitz JT, Hoptman MJ, Leitman DI, et al. The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. Psychol Med. 2014;44(1):25-36. doi:10.1017/S032917130834
10. Leitman DI, Hoptman MJ, Foxe JJ, et al. The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents. Am J Psychiatry. 2007;164(3):474-482. doi:10.176/ajp.207.164.3.474
11. Pinheiro AP, Del Re E, Mezin J, et al. Sensorybased and higher-order operations contribute to abnormal emotional prosody processing in schizophrenia: an electrophysiological investigation. Psychol Med. 2013;43(3):603-618. doi:10.1017/S03291712013X
12. Kantrowitz JT, Scaramello N, Jakubovitz A, et al. Amusia and protolanguage impairments in schizophrenia. Psychol Med. 2014;44(13):2739-2748. doi:10.1017/S032917140373
13. Wynn JK, Sugar C, Horan WP, et al. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol Psychiatry. 2010;67(10):940-947. doi:10.1016/j.biopsych.209.1.024
14. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005;62(2):127-136. doi:10.101/archpsyc.62.2.127
15. Kaur M, Lagopoulos J, Ward PB, et al. Mismatch negativity/P3a complex in young people with psychiatric disorders: a cluster analysis. PLoS ONE. 2012;7(12):e51871. doi:10.1371/journal.pone.051871
16. Friedman T, Sehatpour P, Dias E, et al. Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia. Biol Psychiatry. 2012;71(6):521-529. doi:10.1016/j.biopsych.201.10.037
17. Revheim N, Corcoran CM, Dias E, et al. Reading deficits in schizophrenia and individuals at high clinical risk: relationship to sensory function, course of illness, and psychosocial outcome. Am J Psychiatry. 2014;171(9):949-959. doi:10.176/api.ajp.2014.1309196
18. Vinogradov S, Fisher M, de Villers-Sidani E. Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology. 2012;37(1):43-76. doi:10.1038/np.201.251
19. Fisher M, Holland C, Merzenich MM, et al. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009;166(7):805-811. doi:10.176/api.ajp.209.08050757
20. Keefe RS, Vinogradov S, Medalia A, et al. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry. 2012;73(7):1016-1022. doi:10.408/JCP.1m0710
21. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery. Los Angeles, CA: MATRICS Assessment, Inc; 2006.
22. Terry AV Jr, Mahadik SP. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther. 2007;320(3):961-968. doi:10.124/jpet.106.106047
23. Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23(11):1373-1382. doi:10.1016/j.euroneuro.2013.08.03
24. First MB, Spitzer RL, Gibbon M, et al. Structural Clinical Interview for DSM-IV Axis I Disorders (SCID-IV). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1997.
25. Holdnack HA. Wechsler Test of Adult Reading: WTAR. San Antonio, TX: The Psychological Corporation; 2001.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261
27. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212:11-19. doi:10.1/j.160-047.1970.tb0206.x
28. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994;11(3):239-244. doi:10.1016/0920-964(94)9017-5
29. Medalia A, Revheim N, Herlands T. Cognitive Remediation for Psychological Disorders, Therapist Guide. New York, NY: Oxford University Press; 2009. doi:10.1093/med:psych/9780195383713.01.01
30. Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007;33(6):1364-1372. doi:10.1093/schbul/sbm014
31. Ventura J, Reise SP, Keefe RS, et al. The Cognitive Assessment Interview (CAI): reliability and validity of a brief interviewbased measure of cognition. Schizophr Bull. 2013;39(3):583-591. doi:10.1093/schbul/sbs01
32. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology Revised. Bethesda, MD: MD National Institute of Mental Health; 1976.
33. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672
34. Choi J, Mogami T, Medalia A. Intrinsic Motivation Inventory: an adapted measure for schizophrenia research. Schizophr Bull. 2010;36(5):966-976. doi:10.1093/schbul/sbp030
35. Bruder GE, Alschuler DM, Kroppmann CJ, et al. Heterogeneity of auditory verbal working memory in schizophrenia. J Abnorm Psychol. 2011;120(1):88-97. doi:10.1037/a02161
36. Wexler BE, Stevens AA, Bowers AA, et al. Word and tone working memory deficits in schizophrenia. Arch Gen Psychiatry. 1998;55(12):1093-1096. doi:10.101/archpsyc.5.12.1093
37. Loebel AD, Siu CO, Cucchiaro JB, et al. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014;19(2):197-205. doi:10.1017/S10928529130904
38. Treau F, Antonius D, Nolan K, et al. Immediate affective motivation is not impaired in schizophrenia. Schizophr Res. 2014;159(1):157-163. doi:10.1016/j.schres.2014.08.01
39. Fervaha G, Zakzanis KK, Foussias G, et al. Motivational deficits and cognitive test performance in schizophrenia. JAMA Psychiatry. 2014;71(9):1058-1065. doi:10.101/jamapsychiatry.2014.105
40. Gard DE, Sanchez AH, Cooper K, et al. Do people with schizophrenia have difficulty anticipating pleasure, engaging in effortful behavior, or both? J Abnorm Psychol. 2014;123(4):771-782. doi:10.1037/abn05
41. Saperstein AM, Medalia A. The role of motivation in cognitive remediation for people with schizophrenia. Curr Top Behav Neurosci. 2015. doi:10.107/78542015373